title: Established, emerging and future applications of FDG-PET/CT in the uterine cancer.
abstract: Integrated positron emission tomography/computed tomography (PET/CT) with 2-[¹⁸F]fluoro-2-deoxy-D-glucose (FDG) is a useful technique to acquire both glucose metabolic and anatomic imaging data using a single device in a single diagnostic session and has opened a new field in clinical oncologic imaging. FDG-PET/CT has been used successfully for the staging, optimization of treatment, re-staging, therapy monitoring, and prognostic prediction of uterine cervical cancer and endometrial cancer as well as various malignant tumours. The present review discusses the current role of FDG-PET/CT in the management of uterine cancer, discussing its usefulness and limitations in the imaging of these patients.
authors.affiliation: PET Diagnosis, Institute of Biomedical Research and Innovation, Kobe, Japan. kitajima@med.kobe-u.ac.jp
authors.forename: K
authors.initials: K
authors.lastname: Kitajima
authors.forename: K
authors.initials: K
authors.lastname: Murakami
authors.forename: Y
authors.initials: Y
authors.lastname: Kaji
authors.forename: S
authors.initials: S
authors.lastname: Sakamoto
authors.forename: K
authors.initials: K
authors.lastname: Sugimura
mesh_terms: D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D049268:Positron-Emission Tomography / Q000379:methods / Q000639:trends*; D011379:Prognosis; D019275:Radiopharmaceuticals; D014057:Tomography, X-Ray Computed / Q000379:methods / Q000639:trends*; D016896:Treatment Outcome; D014594:Uterine Neoplasms / Q000000981:diagnostic imaging*
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18